Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EVT 101 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | EVT 101 8 mg capsule |
| 2 | EXPERIMENTAL | EVT 101 15 mg capsule |
| 3 | PLACEBO_COMPARATOR | Matching placebo capsule |
| Name | Type | Description |
|---|---|---|
| EVT 101 | DRUG | 8 mg capsule, single oral dose |
| placebo | DRUG | Placebo capsule, single oral dose |
Inclusion Criteria: * Healthy Male volunteers * Body Mass Index between 19 and 29 Exclusion Criteria: * Subjects who received any prescribed medication within 5 half lives or 14 days of the first dose administration whichever is the longer * Subjects who have received any prescribed CNS medicatio...
EVT 101 is an investigational small molecule being studied in human volunteers. It is a novel NMDA NR2B-subtype selective antagonist. The completed Phase 1 trial evaluated its effects on brain function in healthy male volunteers aged 18 years and older in the United Kingdom.
EVT 101 targets the NR2B subtype of the NMDA receptor. It is described as a novel NMDA NR2B-subtype selective antagonist, meaning it selectively blocks this specific receptor subtype. This mechanism was studied in a Phase 1 trial assessing its effects on brain function.
EVT 101 is being developed by Evotec SE, a biopharmaceutical company listed on the stock exchange under the ticker EVO. The company conducted a Phase 1 clinical trial of EVT 101 in the United Kingdom.
EVT 101 is in Phase 1 clinical development. The single trial listed for EVT 101 was a Phase 1 study that has been completed. EVT 101 is an investigational drug and is not approved for any indication.
EVT 101 has one completed clinical trial, registered as NCT00526968. The trial was titled "The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function" and enrolled 19 healthy male volunteers in the United Kingdom. It was a randomized, double-blind, placebo-controlled study.
EVT 101 is a specific NMDA NR2B-subtype selective antagonist. It is not identified as the same as any other drug in the available information. Its selectivity for the NR2B subtype distinguishes it from non-selective NMDA receptor antagonists.